MEF2C and neoplasm: Treatment of FN-RMS cell lines with trametinib, a MEK1/2 tyrosine kinase inhibitor, results in increased expression of differentiation TFs like MYOG and MEF2C, leading to terminal differentiation of tumor cells (Yohe et al., 2018).